Bcl-2 antisense therapy in B-cell malignant proliferative disorders

Asher A Chanan Khan, Myron S. Czuczman

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Overexpression of Bcl-2 oncogene has been clinically associated with an aggressive clinical course, chemotherapy and radiotherapy resistance, and poor survival in patients with malignant B-cell disorders. Patients with relapsed or refractory chronic lymphocytic leukemia, multiple myeloma, or non-Hodgkin's lymphoma have limited therapeutic options. Preclinical and early clinical data have shown that Bcl-2 oncoprotein can be decreased by Bcl-2 antisense therapy. Also, downregulation of Bcl-2 protein can result in reversal of chemotherapy resistance and improved antitumor activity of biologic agents. Various clinical trials are evaluating the role of targeting Bcl-2 as a mechanism to enhance the antitumor potential of chemotherapy and immunotherapy. Early results from these clinical studies are encouraging and confirm the proof of principle for antisense therapy. As current data mature, these trials will hopefully validate preliminary results and establish Bcl-2 antisense as an important addition to the current armamentarium used in the treatment of patients with B-cell neoplasms.

Original languageEnglish (US)
Pages (from-to)261-267
Number of pages7
JournalCurrent Treatment Options in Oncology
Volume5
Issue number4
StatePublished - Aug 2004
Externally publishedYes

Fingerprint

B-Lymphocytes
Drug Therapy
Oncogene Proteins
Biological Factors
B-Cell Chronic Lymphocytic Leukemia
Therapeutics
Multiple Myeloma
Oncogenes
Non-Hodgkin's Lymphoma
Immunotherapy
Radiotherapy
Down-Regulation
Clinical Trials
Survival
Neoplasms
Proteins

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Bcl-2 antisense therapy in B-cell malignant proliferative disorders. / Chanan Khan, Asher A; Czuczman, Myron S.

In: Current Treatment Options in Oncology, Vol. 5, No. 4, 08.2004, p. 261-267.

Research output: Contribution to journalArticle

@article{8de6c98544d0459686577184c7180c6f,
title = "Bcl-2 antisense therapy in B-cell malignant proliferative disorders",
abstract = "Overexpression of Bcl-2 oncogene has been clinically associated with an aggressive clinical course, chemotherapy and radiotherapy resistance, and poor survival in patients with malignant B-cell disorders. Patients with relapsed or refractory chronic lymphocytic leukemia, multiple myeloma, or non-Hodgkin's lymphoma have limited therapeutic options. Preclinical and early clinical data have shown that Bcl-2 oncoprotein can be decreased by Bcl-2 antisense therapy. Also, downregulation of Bcl-2 protein can result in reversal of chemotherapy resistance and improved antitumor activity of biologic agents. Various clinical trials are evaluating the role of targeting Bcl-2 as a mechanism to enhance the antitumor potential of chemotherapy and immunotherapy. Early results from these clinical studies are encouraging and confirm the proof of principle for antisense therapy. As current data mature, these trials will hopefully validate preliminary results and establish Bcl-2 antisense as an important addition to the current armamentarium used in the treatment of patients with B-cell neoplasms.",
author = "{Chanan Khan}, {Asher A} and Czuczman, {Myron S.}",
year = "2004",
month = "8",
language = "English (US)",
volume = "5",
pages = "261--267",
journal = "Current Treatment Options in Oncology",
issn = "1527-2729",
publisher = "Springer New York",
number = "4",

}

TY - JOUR

T1 - Bcl-2 antisense therapy in B-cell malignant proliferative disorders

AU - Chanan Khan, Asher A

AU - Czuczman, Myron S.

PY - 2004/8

Y1 - 2004/8

N2 - Overexpression of Bcl-2 oncogene has been clinically associated with an aggressive clinical course, chemotherapy and radiotherapy resistance, and poor survival in patients with malignant B-cell disorders. Patients with relapsed or refractory chronic lymphocytic leukemia, multiple myeloma, or non-Hodgkin's lymphoma have limited therapeutic options. Preclinical and early clinical data have shown that Bcl-2 oncoprotein can be decreased by Bcl-2 antisense therapy. Also, downregulation of Bcl-2 protein can result in reversal of chemotherapy resistance and improved antitumor activity of biologic agents. Various clinical trials are evaluating the role of targeting Bcl-2 as a mechanism to enhance the antitumor potential of chemotherapy and immunotherapy. Early results from these clinical studies are encouraging and confirm the proof of principle for antisense therapy. As current data mature, these trials will hopefully validate preliminary results and establish Bcl-2 antisense as an important addition to the current armamentarium used in the treatment of patients with B-cell neoplasms.

AB - Overexpression of Bcl-2 oncogene has been clinically associated with an aggressive clinical course, chemotherapy and radiotherapy resistance, and poor survival in patients with malignant B-cell disorders. Patients with relapsed or refractory chronic lymphocytic leukemia, multiple myeloma, or non-Hodgkin's lymphoma have limited therapeutic options. Preclinical and early clinical data have shown that Bcl-2 oncoprotein can be decreased by Bcl-2 antisense therapy. Also, downregulation of Bcl-2 protein can result in reversal of chemotherapy resistance and improved antitumor activity of biologic agents. Various clinical trials are evaluating the role of targeting Bcl-2 as a mechanism to enhance the antitumor potential of chemotherapy and immunotherapy. Early results from these clinical studies are encouraging and confirm the proof of principle for antisense therapy. As current data mature, these trials will hopefully validate preliminary results and establish Bcl-2 antisense as an important addition to the current armamentarium used in the treatment of patients with B-cell neoplasms.

UR - http://www.scopus.com/inward/record.url?scp=4344661301&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4344661301&partnerID=8YFLogxK

M3 - Article

VL - 5

SP - 261

EP - 267

JO - Current Treatment Options in Oncology

JF - Current Treatment Options in Oncology

SN - 1527-2729

IS - 4

ER -